IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Show more...
首席执行官
Mr. Will Martin
员工
44
国家
瑞典
ISIN
SE0008321202
WKN
000A2H5NT
上市
0 Comments
分享你的想法
FAQ
Irras AB 今天的股价是多少?▼
IRRAS.ST 当前价格为 SEK0.16 SEK,在过去 24 小时内下跌了 -1.11%。在图表上更密切关注 Irras AB 股票的表现。
Irras AB 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Irras AB 的股票以代码 IRRAS.ST 进行交易。